Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 Three-Year Analysis)

Plain-language summary

This phase 3, double-blind, randomized controlled trial found that three years of tirzepatide treatment in participants with obesity and prediabetes produced substantial, sustained weight reduction and a markedly lower risk of progression to type 2 diabetes compared to placebo. The study followed 1,032 participants with both obesity and prediabetes from the larger SURMOUNT-1 cohort. Results position tirzepatide as a dual GIP/GLP-1 receptor agonist with significant long-term metabolic benefits in preclinical research populations.